U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07731919) titled 'Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis' on July 23.
Brief Summary: This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days. The study will compare different dose levels of ALX1 to help identify appropriate doses for future research based on safety, tolerability, and changes in predictive biomarkers.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Bronchiectasis Adult
Intervention:
DRUG: ALX1
Dose Formulation: Solution f...